Fintel reports that on October 6, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy ...

The company was one of many to get letters last month from the US Food and Drug Administration calling out what the agency ...

Our RNAi play came from the understanding that personalization and the development of curated therapies are the future of ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Throughout the last three months, 27 analysts have evaluated Alnylam Pharmaceuticals (NASDAQ: ALNY ), offering a diverse set ...

ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on September 19 and ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $304.00. The company’s shares closed last ...

Across the recent three months, 24 analysts have shared their insights on Alnylam Pharmaceuticals (NASDAQ:ALNY), expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...

As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the ...